Avalo Therapeutics, Inc. (AVTX) Total liabilities 2016–2025
Avalo Therapeutics, Inc. (AVTX) total liabilities at each fiscal year-end, per SEC filings.
$33.4MFY2025 · since FY2016: $5.6M → $33.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $33.4M | +88.8% |
| FY2024 | $17.7M | +29.3% |
| FY2023 | $13.7M | -69.1% |
| FY2022 | $44.3M | -22.5% |
| FY2021 | $57.1M | +197.7% |
| FY2020 | $19.2M | +27.0% |
| FY2019 | $15.1M | -69.4% |
| FY2018 | $49.3M | +230.1% |
| FY2017 | $14.9M | +168.7% |
| FY2016 | $5.6M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice